# Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy

Study · id `cardio:ct-nct01288443` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01288443](<https://clinicaltrials.gov/study/NCT01288443>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01288443

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 183 participants.

## Technical summary

Registry record NCT01288443. Randomized; quadruple masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2011-12 (actual). Results posted on 2015-09-24.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 183 participants (enrolled count; ClinicalTrials.gov record NCT01288443, source copy `cardio:ctgov-nct01288443-2015-09-24`, retrieved 2026-10-31)
- Start date: 2011-01 (registry gives no type) (ClinicalTrials.gov record NCT01288443, source copy `cardio:ctgov-nct01288443-2015-09-24`, retrieved 2026-10-31)
- Primary completion: 2011-12 (actual) (ClinicalTrials.gov record NCT01288443, source copy `cardio:ctgov-nct01288443-2015-09-24`, retrieved 2026-10-31)
- Completion: 2011-12 (actual) (ClinicalTrials.gov record NCT01288443, source copy `cardio:ctgov-nct01288443-2015-09-24`, retrieved 2026-10-31)
- Results first posted: 2015-09-24 (ClinicalTrials.gov record NCT01288443, source copy `cardio:ctgov-nct01288443-2015-09-24`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT01288443, source copy `cardio:ctgov-nct01288443-2015-09-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01288443-2015-09-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy
- Condition: Hypercholesterolemia
- Intervention (Drug): Alirocumab
- Intervention (Drug): Placebo (for alirocumab)
- Intervention (Drug): Atorvastatin
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY
- Collaborator: Regeneron Pharmaceuticals
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Alirocumab (`cardio:alirocumab`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)
- Registry lists this organization as a collaborator: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy (`cardio:pubmed-22463922`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials) (`cardio:pubmed-25060413`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy (`cardio:pubmed-26586732`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: b20ccdae9ec4b1597c4b638f4e331bfe8d7d06b1b1aa02cfa959828ad0475a42
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
